Advertisement

Related Videos

Amit Sanyal, MD: A Clinician’s Perspective

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Welcome and Introduction to Vi3C

Opening Session Panel Discussion

Advertisement

Advertisement




Jun
09
Today In Oncology
Daraxonrasib Nearly Doubles Survival in Previously Treated Metastatic Pancreatic Cancer
Teclistamab in Previously Treated Multiple Myeloma
Addition of Talazoparib to Enzalutamide in Metastatic Androgen Pathway Modulation–Sensitive Prostate Cancer
Pooled Analysis of 5-Year Outcomes With Ultra-Hypofractionated SABR in Primary Renal Cell Carcinoma
Sunvozertinib in NSCLC With EGFR Exon 20 Insertion Mutations
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo